ClinicalTrials.gg
CompletedNCT03330132PIVOTUpdated May 15, 2026

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

A Phase 4 interventional study of Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation) in Influenza, Human, sponsored by The University of Hong Kong. Completed at 1 site in China. Open to participants aged 65 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by The University of Hong Kong · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,861
Allocation
Randomized
Ages
65 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.

Enrollment
5th of 22
1,861 · median 549
Started
2017
with 3 others
Phase 4
3 of 22
1 open now
Registered
16th of 22
by date
Lead sponsor
1 of 22
The University of Hong Kong

Among the 22 studies testing MF59 in Influenza, Human, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 3 in phase 4, and was the 16th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MF59

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years to 82 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing MF59 in Influenza, Human, or all of them as a file.
02

Study summary

This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.

Read the detailed description

Background: The typical vaccination strategy of annual administration with inactivated trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) may provide suboptimal protection to older adults in a location with prolonged periods of influenza activity because of the weaker immune response of older adults to vaccination and because of post-vaccination waning in protection over the course of a year. We hypothesize that in a subtropical or tropical location with prolonged circulation of influenza viruses, the higher antibody titers over years achieved after receipt of annual high-dose vaccine, MF59-adjuvanted vaccine or recombinant haemagglutinin (HA) vaccine, or different vaccination strategies of their combinations with or without the standard vaccine, might lead to greater protection than annual receipt of standard vaccines.

Aim: To test the immune profiles over time of older adults following different influenza vaccination strategies.

Design and subjects: Initially a 4-year immunogenicity study with a randomized controlled design among 2200 older adults aged 65-82 years. We will enroll participants who are willing to receive annual influenza vaccination from the general community including community centres and day-care centres. Eligible individuals will be randomly allocated to ten intervention groups (i.e. annual standard QIV, annual MF59-adjuvanted TIV, annual high-dose TIV, annual recombinant-HA QIV, and six combinations of their alternate annual use) consisting of four rounds of vaccination before each winter influenza season and followed up for 4 years. For each round of vaccination, blood samples for immunological tests will be collected before vaccination and 30 and 182 days after vaccination in all participants, and also at 7, 91 and 273 days after vaccination in a subset of 10% of the participants. Acute illnesses among participants will be monitored by active surveillance efforts during influenza seasons. The vaccine formulation in each round of vaccination will be updated for each season according to WHO recommendations.

Study extension: In years 5-8, all participants will receive the recombinant-HA QIV once per year before each winter influenza season, and their receipt of COVID-19 vaccines will also be recorded. Samples will be collected at the same timepoints to monitor immune responses to influenza vaccination and how responses are affected by prior vaccination history.

Main outcome measures: Antibody titers measured by haemagglutination-inhibition assays, which is an established correlate of protection, in addition to other measurements on humoral and cell-mediated immune responses in the ten intervention groups each year.

03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
65 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal influenza vaccine and is willing to receive annual influenza vaccination

Exclusion criteria

Exclusion Criteria:

  • Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix 1a: Recruitment Screening Log) or significant cognitive impairment and are not competent to give their consent.
  • Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:

    • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component, including egg protein;
    • Moderate or severe acute illness with or without fever after any previous influenza vaccination; or
    • A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination.
  • Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:

    • bleeding disorders
    • habitually taking anticoagulants (with the exception of antiplatelets such as aspirin).
  • Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,861 participants (actual)

Study arms

  • Active comparator
    Standard vaccine

    Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Standard inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating standard vaccine & adjuvanted vaccine

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating adjuvanted vaccine & standard vaccine

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating standard vaccine and high-dose vaccine

    Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating high-dose vaccine and standard vaccine

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating adjuvanted vaccine and high-dose vaccine

    Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating high-dose vaccine and adjuvanted vaccine

    Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)

  • Experimental
    High-dose vaccine

    Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: High-dose inactivated influenza vaccine (NH formulation)

  • Experimental
    Adjuvanted vaccine

    Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

  • Experimental
    Recombinant vaccine

    Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

  • Experimental
    Alternating recombinant vaccine and adjuvanted vaccine

    Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.

    Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

Interventions

  • BiologicalStandard inactivated influenza vaccine (NH formulation)

    0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

  • 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

  • BiologicalHigh-dose inactivated influenza vaccine (NH formulation)

    0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

  • BiologicalRecombinant hemagglutinin inactivated influenza vaccine (NH formulation)

    0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

06

What researchers measure

Primary outcomes

  1. Difference in antibody titres

    The difference in antibody titres of participants measured by haemagglutination-inhibition (HAI) assay, evaluated by (1) the proportion of participants who achieve a target rise in antibody titre against each of the vaccine strains at 30 days, and (2) the geometric mean titre (GMT) ratios between the two groups against each of the vaccine strains at 30 days and 182 days. (The targeted rise in antibody titre is defined as the percentage of subjects with either a pre-vaccination HAI titre \<10 and a post-vaccination HAI titre ≥40, or a pre-vaccination HAI titre ≥10 and a minimum four-fold rise in post-vaccination HAI antibody titre.)

    Time frame: 30 and 182 days after each vaccination

Secondary outcomes

  1. Seroprotection

    The proportion of participants who achieve seroprotection defined as an HAI titre ≥40 after each vaccination before the winter seasons.

    Time frame: 30 days after each vaccination

  2. CMI responses

    The vaccine-induced influenza-specific CD4+ and CD8+ T cell responses 7 days post- vaccination, proxy by anti-viral IFNγ production evaluated by Intracellular Cytokine Staining (ICS) assay. Responses for these and other relevant biomarkers are compared to baseline at the time of vaccination.

    Time frame: . 7 days after each vaccination

  3. Adverse events

    The rate of adverse events within 30 days after vaccination for each round of vaccination.

    Time frame: 30 days after each vaccination

  4. PCR confirmed infection

    The rate of PCR-confirmed influenza infection in each round of the study.

    Time frame: 182 days after each vaccination

07

Study locations

1 site
  • The University of Hong Kong
    Hong Kong, China
08

References and documents

Publications

  • Daulagala P, Leung YWY, Luk LLH, Ho F, Chu SHN, Lin J, Cheng SMS, Leung NHL, Eichelberger MC, Peiris M, Iuliano AD, Thompson MG, Cowling BJ, Yen HL. Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial. J Infect Dis. 2026 Apr 29;233(4):e1022-e1030. doi: 10.1093/infdis/jiaf616. PubMed 41359521 ↗
  • Fox A, Sanchez-Ovando S, Carolan L, Hadiprodjo AJ, Chen Y, Ho F, Cheng SMS, Thompson MG, Iuliano AD, Levine MZ, Valkenburg SA, Ip DKM, Peiris JSM, Sullivan SG, Cowling BJ, Leung NHL. Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist. Clin Infect Dis. 2025 Nov 6;81(4):e192-e201. doi: 10.1093/cid/ciaf060. PubMed 40178253 ↗
  • Cowling BJ, Thompson MG, Ng TWY, Fang VJ, Perera RAPM, Leung NHL, Chen Y, So HC, Ip DKM, Iuliano AD. Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults. J Infect Dis. 2020 Sep 14;222(8):1383-1391. doi: 10.1093/infdis/jiaa255. PubMed 32407535 ↗
  • Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, Wong JHF, Fang VJ, Li APY, So HC, Ip DKM, Azziz-Baumgartner E, Fry AM, Levine MZ, Gangappa S, Sambhara S, Barr IG, Skowronski DM, Peiris JSM, Thompson MG. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clin Infect Dis. 2020 Oct 23;71(7):1704-1714. doi: 10.1093/cid/ciz1034. PubMed 31828291 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2025, 98 months.

Of 101 non-industry phase 4 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's 98 months is above that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2017
First posted
Nov 6, 2017
StartActual
Oct 7, 2017
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03330132
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 7, 2017
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 15, 2026

Study contacts

Benjamin J COWLING, PhD
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MF59

Start the discussion